MA51844A - Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 - Google Patents
Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4Info
- Publication number
- MA51844A MA51844A MA051844A MA51844A MA51844A MA 51844 A MA51844 A MA 51844A MA 051844 A MA051844 A MA 051844A MA 51844 A MA51844 A MA 51844A MA 51844 A MA51844 A MA 51844A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- cancer treatment
- treatment methods
- ctla4
- ctla4 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630038P | 2018-02-13 | 2018-02-13 | |
| US201862732828P | 2018-09-18 | 2018-09-18 | |
| US201862740741P | 2018-10-03 | 2018-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51844A true MA51844A (fr) | 2021-05-19 |
Family
ID=67620098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051844A MA51844A (fr) | 2018-02-13 | 2019-02-08 | Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210047409A1 (fr) |
| EP (1) | EP3752193A4 (fr) |
| JP (2) | JP2021513540A (fr) |
| KR (1) | KR20200119845A (fr) |
| CN (1) | CN111727056A (fr) |
| AU (2) | AU2019222517A1 (fr) |
| BR (1) | BR112020015915A8 (fr) |
| CA (1) | CA3090996A1 (fr) |
| MA (1) | MA51844A (fr) |
| MX (1) | MX2020008446A (fr) |
| WO (1) | WO2019160755A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2170959B1 (fr) | 2007-06-18 | 2013-10-02 | Merck Sharp & Dohme B.V. | Anticorps dirigés contre le récepteur humain de mort programmée pd-1 |
| CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
| KR20220149740A (ko) * | 2020-03-05 | 2022-11-08 | 머크 샤프 앤드 돔 엘엘씨 | Pd-1 길항제, ctla4 길항제 및 렌바티닙 또는 그의 제약상 허용되는 염의 조합물을 사용하여 암을 치료하는 방법 |
| EP4114863A4 (fr) * | 2020-03-05 | 2024-04-24 | Merck Sharp & Dohme LLC | Méthodes de traitement du cancer ou d'une infection faisant appel à une association d'un anticorps anti-pd-1, d'un anticorps anti-ctla4 et d'un anticorps anti-tigit |
| WO2021213523A1 (fr) * | 2020-04-24 | 2021-10-28 | 信达生物制药(苏州)有限公司 | Utilisations d'une combinaison d'anticorps anti-pd-1 et d'anticorps anti-ctla-4 dans la prévention ou le traitement du cancer |
| TW202305009A (zh) * | 2021-04-08 | 2023-02-01 | 美商默沙東有限責任公司 | 以皮下投予抗pd1抗體治療癌症之方法 |
| TW202325738A (zh) * | 2021-10-29 | 2023-07-01 | 美商昂科Ｃ４公司 | 抗ctla-4抗體給藥方案 |
| CN113933520B (zh) * | 2021-11-15 | 2023-06-20 | 邹灵龙 | 一种通用型抗体药血药浓度检测的单克隆抗体试剂组合、检测方法和试剂盒 |
| WO2024002074A1 (fr) * | 2022-06-28 | 2024-01-04 | 齐鲁制药有限公司 | Composition pharmaceutique comprenant un anticorps mixte d'anti-ctla4 et anti-pd1 et son utilisation thérapeutique |
| WO2024055005A2 (fr) * | 2022-09-09 | 2024-03-14 | Adagene Pte. Ltd. | Anticorps anti-ctla4 activables pour le traitement du cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3214175A1 (fr) * | 1999-08-24 | 2017-09-06 | E. R. Squibb & Sons, L.L.C. | Anticorps ctla-4 humains et leurs utilisations |
| NZ563193A (en) * | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| EP2170959B1 (fr) * | 2007-06-18 | 2013-10-02 | Merck Sharp & Dohme B.V. | Anticorps dirigés contre le récepteur humain de mort programmée pd-1 |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| EP3185866A1 (fr) * | 2014-08-25 | 2017-07-05 | Pfizer Inc. | Combinaison d'un antagoniste de pd-1 et d'un inhibiteur d'alk dans le traitement du cancer |
| US20160362489A1 (en) * | 2015-04-28 | 2016-12-15 | Bristol-Myers Squibb Company | Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody |
| EP3858859A1 (fr) * | 2015-07-14 | 2021-08-04 | Bristol-Myers Squibb Company | Méthode de traitement du cancer à l'aide de contrôle immunitaire ; anticorps qui se lie à une mort programmée-1 receptor (pd-1) ou mort programmée ligand 1 (pd-l1) |
| US20180222989A1 (en) * | 2015-08-04 | 2018-08-09 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| US20180230431A1 (en) * | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
| AU2016369537B2 (en) * | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
| EP3213768A1 (fr) * | 2016-03-01 | 2017-09-06 | LODOCO CLINICAL Kft | Combination d'une dose base d'une blockade de checkpoint immnunologique avec une dose élevée de il-2 pour le traitement du cancer métastatique |
| WO2017210453A1 (fr) * | 2016-06-02 | 2017-12-07 | Bristol-Myers Squibb Company | Blocage de pd-1 avec du nivolumab dans le lymphome de hodgkin réfractaire |
| CN109476753A (zh) * | 2016-06-03 | 2019-03-15 | 百时美施贵宝公司 | 用于治疗肿瘤的方法的抗-pd-1抗体 |
| KR102515509B1 (ko) * | 2016-06-03 | 2023-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 |
| JP2020518598A (ja) * | 2017-05-02 | 2020-06-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 単独およびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法 |
-
2019
- 2019-02-08 MA MA051844A patent/MA51844A/fr unknown
- 2019-02-08 KR KR1020207026005A patent/KR20200119845A/ko unknown
- 2019-02-08 CN CN201980013384.1A patent/CN111727056A/zh active Pending
- 2019-02-08 JP JP2020542952A patent/JP2021513540A/ja active Pending
- 2019-02-08 AU AU2019222517A patent/AU2019222517A1/en not_active Abandoned
- 2019-02-08 WO PCT/US2019/017188 patent/WO2019160755A1/fr unknown
- 2019-02-08 US US16/966,988 patent/US20210047409A1/en active Pending
- 2019-02-08 CA CA3090996A patent/CA3090996A1/fr active Pending
- 2019-02-08 BR BR112020015915A patent/BR112020015915A8/pt unknown
- 2019-02-08 EP EP19754385.3A patent/EP3752193A4/fr active Pending
- 2019-02-08 MX MX2020008446A patent/MX2020008446A/es unknown
-
2023
- 2023-07-26 AU AU2023208115A patent/AU2023208115A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000161A patent/JP2024038250A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019222517A1 (en) | 2020-08-13 |
| CN111727056A (zh) | 2020-09-29 |
| RU2020129075A (ru) | 2022-03-14 |
| BR112020015915A8 (pt) | 2023-01-31 |
| BR112020015915A2 (pt) | 2020-12-15 |
| AU2023208115A1 (en) | 2024-01-18 |
| JP2024038250A (ja) | 2024-03-19 |
| MX2020008446A (es) | 2020-09-28 |
| WO2019160755A1 (fr) | 2019-08-22 |
| KR20200119845A (ko) | 2020-10-20 |
| US20210047409A1 (en) | 2021-02-18 |
| JP2021513540A (ja) | 2021-05-27 |
| CA3090996A1 (fr) | 2019-08-22 |
| EP3752193A1 (fr) | 2020-12-23 |
| EP3752193A4 (fr) | 2022-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51844A (fr) | Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 | |
| MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
| MA52789A (fr) | Méthodes de traitement du cancer avec des anticorps anti-pd-1 | |
| MA51631A (fr) | Anticorps anti-pd1 et méthodes de traitement | |
| MA47206A (fr) | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 | |
| MA51208A (fr) | Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancer | |
| MA47208A (fr) | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
| RS61510B1 (sr) | Anti pd-1 i anti-lag3 antitela za lečenje kancera | |
| MA51815A (fr) | Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| MA53506A (fr) | Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules | |
| EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
| MA56212A (fr) | Compositions et méthodes de traitement du cancer | |
| MA40576B1 (fr) | Anticorps et immunoconjugués anti-her2 | |
| MA51677A (fr) | Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
| BR112017009297A2 (pt) | anticorpos antifator de complemento c1q humanizados e usos dos mesmos | |
| MA45675A (fr) | Méthodes et compositions permettant le traitement du cancer | |
| MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
| MA47613A (fr) | Compositions et procédés de traitement du cancer | |
| MA46842A (fr) | Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 | |
| EA201990778A1 (ru) | Анти-il-33 антитела и их применение | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| EA201790529A1 (ru) | Новые антитела против mfi2 и способы их применения | |
| MA47362A (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif |